Experts are carefully copyrightining Semorinemab , a experimental therapeutic targeting tau protein aggregates, a crucial hallmark of Alzheimer's . Unlike many past attempts focused on amyloid plaques, Semorinemab intends to specifically diminish these damaging tau formations in the cerebrum . Prelim